Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 47,300 shares, a drop of 23.1% from the December 31st total of 61,500 shares. Based on an average daily trading volume, of 122,300 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Parkman Healthcare Partners LLC lifted its stake in shares of Entera Bio by 2.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after purchasing an additional 9,558 shares during the period. Perigon Wealth Management LLC purchased a new position in Entera Bio during the fourth quarter valued at $325,000. Finally, Signature Estate & Investment Advisors LLC bought a new stake in shares of Entera Bio during the 3rd quarter valued at $90,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Trading Up 2.1 %

Shares of ENTX opened at $2.38 on Thursday. Entera Bio has a 1-year low of $0.68 and a 1-year high of $3.35. The firm has a market capitalization of $85.17 million, a price-to-earnings ratio of -9.15 and a beta of 1.49. The firm’s 50-day moving average price is $2.16 and its 200-day moving average price is $1.91.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.